- Report
- November 2021
- 844 Pages
Global
From €4551EUR$5,000USD£3,901GBP
- Report
- November 2021
- 575 Pages
Global
From €3640EUR$4,000USD£3,121GBP
- Report
- March 2023
- 300 Pages
Global
From €3249EUR$3,570USD£2,785GBP
Memantine is a drug used to treat symptoms of Alzheimer's disease and other forms of dementia. It is classified as an NMDA receptor antagonist, which works by blocking the action of a neurotransmitter called glutamate. This helps to reduce the symptoms of dementia, such as memory loss, confusion, and difficulty with language. Memantine is also used to treat Parkinson's disease, Huntington's disease, and multiple sclerosis.
Memantine is a relatively new drug, having been approved by the FDA in 2003. It is available in both oral and intravenous forms, and is typically prescribed in combination with other drugs. It is generally well-tolerated, with few side effects.
The memantine market is a growing one, with a number of companies offering products. These include Novartis, Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Other companies, such as Actavis, Lupin, and Dr. Reddy's Laboratories, also offer generic versions of the drug. Show Less Read more